Shilpa Medicare Ltd

With a decisive break above Rs 578 on 10 Jun 2026, Shilpa Medicare Ltd has reached a fresh 52-week high, extending its impressive 21.62% gain over the past year against the Sensex’s decline of 9.63%. This milestone reflects a strong technical momentum that has been building steadily over recent sessions.

Surging past its previous peaks, Shilpa Medicare Ltd touched a fresh 52-week high of Rs 578 on 09 Jun 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained outperformance relative to its sector and the broader market.

The Sensex edged up 0.55% on 09 Jun 2026, but Shilpa Medicare Ltd outpaced the broader market with a 7.23% gain, reaching an intraday high of Rs 557.2. This 3.76-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific rally rather than a market-wide lift.

Shilpa Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 09 June 2026, providing investors with the latest insights into its performance and outlook.

With a decisive surge to Rs 551.25 on 8 Jun 2026, Shilpa Medicare Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally stands out amid a broader market environment where the Sensex is under pressure, highlighting the stock's relative strength and technical robustness.

Shilpa Medicare Ltd has demonstrated a notable shift in technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underpinned by strong signals from key technical indicators including MACD, Bollinger Bands, and moving averages, suggesting a positive outlook for the small-cap pharmaceutical and biotechnology company amid a robust price rally.

Shilpa Medicare Ltd has exhibited a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early June 2026. Despite a modest day change of 0.23%, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, reflecting a cautious but optimistic outlook within the Pharmaceuticals & Biotechnology sector.

Shilpa Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

With a decisive surge to Rs 529.8 on 25 Jun 2026, Shilpa Medicare Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes amid a backdrop of strong technical signals and sustained outperformance relative to its sector and the broader market.

Shilpa Medicare Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling renewed investor interest and potential upside in the pharmaceuticals and biotechnology sector.

Shilpa Medicare Ltd., a Raichur-based pharmaceutical company specialising in active pharmaceutical ingredients (APIs) and formulations, delivered a remarkable turnaround in Q4 FY26, with consolidated net profit surging 642.87% year-on-year to ₹107.79 crores from ₹14.51 crores in Q4 FY25. The stellar performance was driven by robust revenue growth of 32.09% YoY and significant margin expansion, marking the company's strongest quarterly performance on record.

With a decisive surge to Rs 515 on 22 Jun 2026, Shilpa Medicare Ltd has reached a fresh 52-week high, marking a 35.17% gain over the past year and significantly outperforming the Sensex, which declined 6.88% in the same period.

The Sensex advanced 0.33% on 22 May 2026, yet Shilpa Medicare Ltd outpaced the broader market with a robust 7.78% gain, touching an intraday high of Rs 511.05. This 7.79 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Shilpa Medicare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a nuanced shift in its technical momentum. While some indicators suggest a cautiously optimistic outlook, others point to underlying bearish pressures, reflecting a complex market sentiment as the stock navigates key resistance levels near ₹477.

Shilpa Medicare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.